NovelMed Therapeutics

Founded in Cleveland, NovelMed Therapeutics is a privately-held biotechnology company dedicated to developing innovative therapies for both orphan and non-orphan diseases. The company's core mission is to transform patients' lives by targeting specific parts of the immune system involved in disease processes. NovelMed specializes in complement-based therapies and offers a portfolio of neutralizing monoclonal antibodies aimed at treating acute and chronic conditions with significant market potential and unmet medical needs.

Notable affiliated individuals and investors include experienced biotech professionals and venture capitalists committed to advancing medical science. Key achievements for NovelMed include the discovery of a single therapy for both Wet-AMD and Dry-AMD, as well as pioneering first-in-class treatments for hemolytic disorders like PNH and rare kidney diseases. The company's innovative approach has had a substantial impact on the biotech industry, particularly in the development of treatments for complex and rare diseases.